AHAC SEC filings, in plain English
Everything Alpha Healthcare Acquisition Corp. has filed with the SEC that we hold — 40 filings, newest first, 4 with a plain-English summary of what changed and why it matters. Every row links to the primary document on EDGAR, so you can check the source rather than trust us.
The feed
live EDGAR captureNew filings appear here within minutes of hitting EDGAR; summaries follow once the pipeline has read them.
What changed: Q2 2026 10-Q of Humacyte, Inc. (Nasdaq: HUMA), with 277,798,105 shares of common stock outstanding as of August 10, 2026. Why it matters: This summary is drawn from the cover page and forward-looking section of the report; the financial statements are not covered here. The quarter's figures are stated in the company's earnings release filed the same day (accession 0001104659-26-094440).
going-concern doubtnothing moved · 1 with no prior record of ours
- Going-concern doubt
- stated · unchanged
The clause …“sales on a timely basis and/or obtain additional capital. These factors raise substantial doubt about the Company’s ability to continue as a going concern. The future viability of the Company is dependent on its ability to generate cash”…
Read from stored SEC filing text by a regex — no model is involved — and each side links to the filing it came from. “Not previously extracted” is a statement about our record, not about the company: the clause may be present in wording we do not match.
What changed: Exhibit 99.1 to an 8-K of Humacyte, Inc. (Nasdaq: HUMA): the August 12, 2026 press release reporting Q2 2026 results and a business update. Second quarter Symvess sales were $0.4 million versus $0.1 million a year earlier. Why it matters: The V012 result is an interim analysis of 80 patients and the sBLA has not been filed; approval for dialysis access would be a new indication beyond the existing extremity vascular injury approval. Commercial Symvess revenue remains $0.4 million a quarter.
What changed: Humacyte, Inc., the Alpha Healthcare Acquisition Corp. successor, received a letter from Nasdaq staff on July 31, 2026 stating that for the 30 consecutive business days ended July 30, 2026 the bid price of its common stock closed below the $1.00 minimum required for continued listing on the Nasdaq Global Select Market under Listing Rule 5450(a)(1). Under Rule 5810(c)(3)(A) it has an initial 180 calendar days, until January 27, 2027, to regain compliance by closing at $1.00 or more for at least ten consecutive business days. The stock continues to trade under HUMA. Why it matters: The deadline is January 27, 2027 and the cure is ten consecutive closes at or above $1.00, which for a company on the Global Select tier means either a genuine re-rating or a reverse split put to stockholders. The filing says the company will consider available options and gives no assurance of compliance. For former AHAC holders the practical risk is a downgrade to the Capital Market tier or delisting, each of which narrows the eligible buyer base well before the deadline arrives.
- What changed vs 2025-11-12going concern APPEARED
going-concern doubt1 moved
- Going-concern doubt
- not statedstated
SpacBrain reads this as the substantial-doubt sentence is in this filing and not in the previous one.
The clause …“sales on a timely basis and/or obtain additional capital. These factors raise substantial doubt about the Company’s ability to continue as a going concern. The future viability of the Company is dependent on its ability to generate cash”…
Read from stored SEC filing text by a regex — no model is involved — and each side links to the filing it came from. “Not previously extracted” is a statement about our record, not about the company: the clause may be present in wording we do not match.
What changed: Humacyte, Inc., the successor to Alpha Healthcare Acquisition Corp., called its annual meeting for June 9, 2026 at 8:00 a.m. Eastern Time in a virtual-only format, record date April 23, 2026, electing John P. Bamforth, Keith Anthony Jones and others as directors. RSU values are struck at the last reported closing price of $0.96 on Nasdaq as of December 31, 2025. The pay-versus-performance table reports a 2025 net loss of $40,833,184 with total shareholder return of $33.80 per $100 invested, against a 2024 net loss of $148,701,234 and TSR of $177.82. Why it matters: A $0.96 share price at December 31, 2025 puts the Nasdaq $1.00 minimum bid requirement immediately in play, and total shareholder return collapsed from $177.82 to $33.80 in a single year - an 81% decline. The net loss narrowed sharply to $40.8 million from $148.7 million, so the burn is being contained, but at a sub-dollar price further equity financing would be heavily dilutive. The Alpha Healthcare trust was released at the de-SPAC.
- What changed vs 2025-03-31going concern APPEARED
going-concern doubt1 moved
- Going-concern doubt
- not statedstated
SpacBrain reads this as the substantial-doubt sentence is in this filing and not in the previous one.
The clause …“Our Financial Position and Need for Additional Funding We have concluded that substantial doubt is deemed to exist concerning our ability to continue as a going concern. The Company will not have sufficient liquidity to fund its”…
Read from stored SEC filing text by a regex — no model is involved — and each side links to the filing it came from. “Not previously extracted” is a statement about our record, not about the company: the clause may be present in wording we do not match.
In plain English
Redemption deadlinethe last day to hand shares back for cash
Set by the filing that calls the meeting. Tender after it and the company is under no obligation to pay you the trust value.
Cash in trust / trust per sharethe cash the company is holding for each public share
Filed quarterly in the 10-Q's XBRL. It earns interest between filings, so the figure on a given day is slightly higher than the last filed one — where we show that we label it an estimate.
Accession numberthe SEC's unique id for one filing
Every figure on this page carries the accession of the filing that states it, so you can open the primary document rather than trust us.